title: Evaluation of the frequency of the IL-28 polymorphism (rs8099917) in patients with chronic hepatitis C using Zip nucleic acid probes, Kerman, Southeast of Iran.
abstract: Polymorphisms in the region of the interleukin IL-28 gene on chromosome 19 have been related with clearance of hepatitis C virus (HCV), a major human pathogen responsible for chronic hepatitis, cirrhosis and hepatocellular carcinoma. About 3% of the world's population is infected with HCV. The long-term response to therapy is influenced by many host and viral factors, and recent evidence has indicated that some host genetic polymorphisms related to IL-28 are the most powerful predictors of virological response in patients with HCV. This study assessed frequency of the IL-28 polymorphism (rs8099917) in 50 patients (39 men and 11 women ) with chronic hepatitis C using ZNA probe real time PCR new method . All patients were tested for genotype of HCV and the HCV viral load. In parallel, the levels of SGOT, SGPT and ALK enzymes were assessed. Treatment using Peg-interferon alpha with ribavirin was conducted for patients and subsequently samples were collected to detect any change in viral load or liver enzyme rates. The overall frequency of the TT allele is 74%, TG allele 20% and GG allele 6% and the percent of patients who had T allele was 84%. Clear reduction in viral load and liver enzymes was reported in patients with the T allele. Especially for genotype 1 which is relatively resistant to treatment, these alleles may have a role in this decline. In conclusion, we showed that IL-28 polymorphism rs8099917 strongly predicts virological response in HCV infection and that real-time PCR with Zip nucleic acid probes is a sensitive, specific and rapid detection method for detection of SNPs which will be essential for monitoring patients undergoing antiviral therapy.
authors.affiliation: Department of Medical Microbiology, Kerman University of Medical Sciences, Kerman, Iran E-mail : hamid2008kmu@gmail.com.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Iranmanesh
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Mollaie
authors.forename: Seyed Alimohammad
authors.initials: SA
authors.lastname: Arabzadeh
authors.forename: Mohammad Javad
authors.initials: MJ
authors.lastname: Zahedi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Fazlalipour
authors.forename: Saeede
authors.initials: S
authors.lastname: Ebrahimi
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000077548:Anaplastic Lymphoma Kinase; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005787:Gene Frequency; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007378:Interleukins / Q000235:genetics*; D007492:Iran; D008297:Male; D008875:Middle Aged; D015341:Nucleic Acid Probes; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020794:Receptor Protein-Tyrosine Kinases / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects; D000095022:Interferon Lambda
chemical_list: D000410:Alanine Transaminase; D000077548:Anaplastic Lymphoma Kinase; D000914:Antibodies, Viral; D000998:Antiviral Agents; D001219:Aspartate Aminotransferases; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D007378:Interleukins; D015341:Nucleic Acid Probes; D011092:Polyethylene Glycols; D020794:Receptor Protein-Tyrosine Kinases; D011994:Recombinant Proteins; D012254:Ribavirin; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C000626173:ALK protein, human; C100416:peginterferon alfa-2a